Adenosine receptors (ARs) have been identified as promising therapeutic targets for
countless pathological conditions, spanning from inflammatory diseases to central nervous …

Many people consume coffee to attenuate increased sleepiness and impaired vigilance and
attention due to insufficient sleep. We investigated in genetically caffeine sensitive men and …

KW-6356 is a novel adenosine A 2A receptor antagonist/inverse agonist that not only blocks
binding of adenosine to adenosine A 2A receptor but also inhibits the constitutive activity of …

Adenosine A2A receptor (A2AR) antagonists are the leading nondopaminergic therapy to
manage Parkinson's disease (PD) since they afford both motor benefits and neuroprotection …

Introduction Unexpected non-apparent and hidden allosteric-binding sites are non-classical
and non-apparent allosteric centers in 3-D X-ray protein structures until orthosteric or …

The adenosine A 2A receptor antagonist/inverse agonist, KW-6356 has been shown to be
effective in Parkinson's disease (PD) patients as monotherapy and as an adjunct therapy to …

Based on a screening of a chemical library of A2A adenosine receptor (AR) antagonists, a
series of di-and tri-substituted adenine derivatives were synthesized and tested for their …

Abstract The 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-lesioned common
marmoset has been used extensively to model Parkinson's disease, l-3, 4 …

The mechanism of propofol‐anesthesia‐induced loss of consciousness (LOC) remains
largely unknown. We speculated that the adenosine A2A receptor serves as a vital …

Neuronal calcium dyshomeostasis has been associated to Parkinson's disease (PD)
development based on epidemiological studies on users of calcium channel antagonists …